IL7 and melanoma: The experiments have proved that IL-7 and TIL1383I TCR-modified T cells without CD3-stimulated co-culture responded well to melanoma, and they overcame the disadvantages of conventional CD3-activated T cells, providing feasible strategies for improving survival in melanoma and other malignant tumors [106].